DrugPatentWatch Database Preview
VIBATIV Drug Profile
» See Plans and Pricing
When do Vibativ patents expire, and what generic alternatives are available?
Vibativ is a drug marketed by Cumberland Pharms and is included in one NDA. There are eleven patents protecting this drug.
This drug has one hundred and twenty-eight patent family members in thirty-five countries.
The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the telavancin hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Vibativ
Vibativ was eligible for patent challenges on September 11, 2013.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 1, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for VIBATIV
| International Patents: | 128 |
| US Patents: | 11 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 14 |
| Clinical Trials: | 13 |
| Patent Applications: | 1,252 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VIBATIV |
| What excipients (inactive ingredients) are in VIBATIV? | VIBATIV excipients list |
| DailyMed Link: | VIBATIV at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for VIBATIV
Generic Entry Date for VIBATIV*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VIBATIV
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Joseph Kuti | Phase 4 |
| Theravance Biopharma, US, Inc. | Phase 4 |
| University of Illinois at Chicago | Phase 1 |
Pharmacology for VIBATIV
| Drug Class | Lipoglycopeptide Antibacterial |
US Patents and Regulatory Information for VIBATIV
Expired US Patents for VIBATIV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | Get Started for $10 | Get Started for $10 |
| Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | Get Started for $10 | Get Started for $10 |
| Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | Get Started for $10 | Get Started for $10 |
| Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | Get Started for $10 | Get Started for $10 |
| Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | Get Started for $10 | Get Started for $10 |
| Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | Get Started for $10 | Get Started for $10 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIBATIV
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 1441680 | Get Started for $10 |
| Argentina | 035333 | Get Started for $10 |
| Hungary | 229370 | Get Started for $10 |
| Portugal | 1292612 | Get Started for $10 |
| Denmark | 2495251 | Get Started for $10 |
| Japan | 3900491 | Get Started for $10 |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VIBATIV
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1292612 | 11C0051 | France | Get Started for $10 | PRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
| 1292612 | 417 | Finland | Get Started for $10 | |
| 1292612 | PA2012002,C1292612 | Lithuania | Get Started for $10 | PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902 |
| 1292612 | PA2012002 | Lithuania | Get Started for $10 | PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902 |
| 1292612 | 122011100062 | Germany | Get Started for $10 | PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
| 1292612 | CA 2011 00033 | Denmark | Get Started for $10 | PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
